Clinician in the Loop Dexcom’s HCP-Specific Continuous Glucose Monitor

Dexcom, Inc. – the leading manufacturer of continuous glucose monitoring systems – has filed a patent for a healthcare professional-specific CGM device designed to support clinicians in setting up patients on monitoring technology and ensuring they understand their data from the outset. The invention addresses the critical gap between device capability and patient comprehension that can limit the real-world impact of continuous glucose monitoring.

The Problem

Continuous glucose monitoring (CGM) technology has transformed diabetes management over the past decade. By providing real-time glucose readings every few minutes, trend arrows and alerts for dangerous glucose levels, CGM systems give people with diabetes an unprecedented window into their metabolic state. Clinical evidence consistently shows that CGM use improves glycaemic control, reduces hypoglycaemia rates and enhances quality of life for people with both type 1 and type 2 diabetes.

Despite this evidence, the full benefit of CGM is frequently not realised in clinical practice. A key challenge is initial patient education: when a patient is first set up on a CGM system, they must learn not only how to use the device but also how to interpret the data it generates and, critically, how to use that data to make decisions about their care. If this education and setup process is poorly supported, patients may understand how to wear the sensor but not how to act meaningfully on the numbers it provides – significantly reducing the clinical impact of the technology.

Consumer-facing CGM devices are designed for ease of use by patients, but they may not be optimally configured for the clinical setup workflow. A clinician setting up a new patient needs a device that allows them to adjust settings for the specific patient’s level of understanding and clinical needs, and to demonstrate the system’s capabilities in a clear and clinically meaningful way. The absence of a dedicated healthcare professional mode in standard CGM devices means this setup workflow has often been improvised rather than systematically supported.

What This Invention Does

Dexcom’s invention describes a CGM device specifically configured for use by healthcare professionals during initial patient system setup. The device includes the standard hardware elements of a CGM system – a housing and circuit capable of receiving signals from a transmitter coupled to an indwelling glucose sensor – combined with a calibration module that converts the sensor signal into clinically meaningful glucose concentration readings in standard clinical units.

The critical innovation is in the user interface, which is designed to receive input data about the patient’s level of understanding and clinical situation. Based on this input, the device changes its operating mode to be appropriate for that specific patient – adjusting how information is displayed, which features are highlighted, and how clinical data is presented to match the patient’s level of comprehension and their specific clinical needs.

This personalised setup capability means that when a clinician is working with a newly diagnosed type 1 diabetes patient with no prior CGM experience, they can configure the device in a way that is appropriate for that patient’s starting point. When working with an experienced insulin pump user transitioning to a new CGM system, they can configure it differently. The device supports the clinician in tailoring the educational and setup experience to the individual patient rather than delivering a one-size-fits-all onboarding process.

Key Features

Healthcare professional-specific device. The CGM device is specifically designed for use by clinicians rather than patients, with features and an interface optimised for the clinical setup and education workflow.

Patient level input capability. The user interface can receive input data about a patient’s level of understanding and clinical status, enabling clinicians to configure the device appropriately for each individual patient.

Mode adaptation based on patient level. Once patient level data is entered, the device operates in a mode specifically suited to that patient’s needs, adjusting the interface, data presentation and features accordingly.

Clinical unit display. A calibration module converts raw sensor signals to glucose concentration in standard clinical units, providing clinically meaningful readings for the healthcare professional during setup.

Transformative data education. The system is designed not just to collect glucose data but to help patients truly understand what the data means and how they can use it to manage their condition – addressing the comprehension gap that often limits CGM effectiveness.

Who Is Behind It?

Dexcom, Inc. is a San Diego-based medical device company and the global leader in continuous glucose monitoring technology. The inventor team for this patent is exceptionally large – comprising over 35 named inventors including Scott M. Belliveau, Naresh C. Bhavaraju, Darin Edward Chum Dew, Eric Cohen, Anna Leigh Davis, Apurv Ullas Kamath, Katherine Yerre Koehler, Peter C. Simpson and many others – reflecting the broad, multi-disciplinary team involved in developing the next generation of Dexcom’s clinical platform. The application is filed through FB Rice Pty Ltd and is a divisional of an earlier filing (AU 2023248147).

Why It Matters

The gap between having access to advanced monitoring technology and actually using it effectively is one of the central challenges in chronic disease management. For diabetes in particular, where daily decision-making about insulin dosing, diet and activity has profound consequences for both short-term safety and long-term health, the quality of the initial patient education and setup experience can determine whether a CGM system transforms a patient’s management or ends up in a drawer.

By recognising that healthcare professionals need a dedicated tool for the setup process – not just a consumer device handed to a clinician – Dexcom is addressing a real clinical workflow gap. A device that allows clinicians to adapt the patient education experience to the individual reduces variation in setup quality, improves patient engagement, and ultimately increases the likelihood that CGM data is used as intended. As CGM adoption expands to broader populations of people with diabetes and new clinical contexts, tools that support high-quality clinical onboarding will become increasingly important to realising the full public health potential of this technology.

---

AU 2026201602 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.